Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02244190
Recruitment Status : Completed
First Posted : September 19, 2014
Last Update Posted : September 19, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
To establish the bioequivalence of the new tipranavir oral solution formulation with the current tipranavir oral solution formulation following single-dose administration. In each case, 500 mg tipranavir was coadministered with 200 mg ritonavir.

Condition or disease Intervention/treatment Phase
Healthy Drug: Tipranavir Drug: Ritonavir Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bioequivalence of Two Different Oral Solutions of 500 mg of Tipranavir (New Formulation vs. Current Formulation) Administered in Combination With 200 mg of Ritonavir (Oral Solution) to Healthy Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)
Study Start Date : April 2008
Actual Primary Completion Date : May 2008

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: new Tipranavir + Ritonavir Drug: Tipranavir
New oral solution (back up) formulation

Drug: Ritonavir
Other Name: Norvir®

Active Comparator: current Tipranavir + Ritonavir Drug: Tipranavir
Other Name: Current oral solution formulation

Drug: Ritonavir
Other Name: Norvir®




Primary Outcome Measures :
  1. AUC0-∞ (area under the concentration-time curve of drug in plasma over the time interval from 0 extrapolated to infinity) for tipranavir [ Time Frame: up to 72 hours after drug administration ]
  2. Cmax (maximum measured concentration of drug in plasma) for tipranavir [ Time Frame: up to 72 hours after drug administration ]

Secondary Outcome Measures :
  1. AUC0-∞ for ritonavir [ Time Frame: up to 72 hours after drug administration ]
  2. Cmax for ritonavir [ Time Frame: up to 72 hours after drug administration ]
  3. AUC0-tz (area under the concentration-time curve of drug in plasma over the time interval from 0 to the time of the last quantifiable data point) [ Time Frame: up to 72 hours after drug administration ]
  4. tmax (time from dosing to the maximum concentration of drug in plasma) [ Time Frame: up to 72 hours after drug administration ]
  5. λz (terminal rate constant of drug in plasma) [ Time Frame: up to 72 hours after drug administration ]
  6. t1/2 (terminal half-life of drug in plasma) [ Time Frame: up to 72 hours after drug administration ]
  7. MRTpo (mean residence time of drug in the body after oral administration) [ Time Frame: up to 72 hours after drug administration ]
  8. CLpo/F (apparent clearance of drug after oral administration) [ Time Frame: up to 72 hours after drug administration ]
  9. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) [ Time Frame: up to 72 hours after drug administration ]
  10. Number of patients with adverse events [ Time Frame: up to 43 days ]
  11. Number of patients with clinically significant findings in vital signs [ Time Frame: up to 43 days ]
  12. Number of patients with clinically significant findings in 12-lead electrocardiogram [ Time Frame: up to 43 days ]
  13. Number of patients with clinically significant findings in laboratory tests [ Time Frame: up to 43 days ]
  14. Assessment of tolerability by investigator on a 4-point scale [ Time Frame: Day 4 of each treatment period ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males and females according to the following criteria based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
  • Age ≥ 18 and ≤ 55 years
  • BMI ≥ 18.5 and ≤ 29.9 kg/m2 (Body Mass Index) and body weight > 55 kg
  • Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation

Exclusion Criteria:

  • Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  • Any evidence of a clinically relevant concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts.
  • Chronic or relevant acute infections
  • History of relevant allergy/hypersensitivity (including allergy to tipranavir or ritonavir or their excipients)
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration of the trial drug or during the trial
  • Cytochrome P 450 (CYP3A4)-inhibiting drugs (e.g. itraconazole, ketoconazole, protease inhibitors, erythromycin, clarithromycin, telithromycin, nefazodone, cyclosporin, verapamil, amiodarone, diltiazem), CYP3A4 inducing drugs (e.g. St. John´s wort [Hypericum perforatum], rifampin, dexamethasone) or CYP3A4 substrates (e.g. triazolam, sertraline); further drugs which might reasonably influence the results of the trial (e.g. drugs which contain polyethylene glycol) or drugs that prolong the QT/corrected QT interval interval (based on the knowledge at the time of protocol preparation) within 14 days prior to first administration of the trial drug or during the trial
  • Participation in another trial with an investigational drug within two months prior to administration of the trial drug or during the trial
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking within 24 hours before or after administration of the trial drug
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration of the trial drug or during the trial)
  • Excessive physical activities (within one week prior to administration of the trial drug or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
  • A history of additional risk factors for Torsades de Pointes (TdP), e.g., heart failure, hypokalaemia, family history of Long QT Syndrome
  • Known hypersensitivity to antiretroviral drugs (marketed or experimental use as part of clinical research studies)
  • Personal or family history of coagulation or bleeding disorders or bleeding tendencies
  • Intake of vitamin E within 14 days prior to the first drug administration of this trial or during the trial
  • Transaminase values (ALT /AST) greater than the upper limit of the normal laboratory reference range during screening

For female subjects:

  • Pregnancy or positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
  • No adequate contraception during the study and until 1 month of study completion, i.e. not any of the following: implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence (for at least 1 month prior to enrolment), vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (incl. hysterectomy). Females who do not have a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide).
  • Lactation period
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02244190    
Other Study ID Numbers: 1182.124
First Posted: September 19, 2014    Key Record Dates
Last Update Posted: September 19, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Ritonavir
Tipranavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors